Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.
BACKGROUND
Viral oncolysis, or virotherapy, is an emerging strategy for the treatment of cancer based on tumor cell killing by virus infection and replication. Oncolytic adenoviruses have shown promise in clinical trials, which demonstrated proof-of-concept for tumor-selective virus replication and a favorable safety profile.


METHODS
We provide an overview of specifications for a novel antitumour approach by oncolytic adenoviruses expressing interleukin and discuss recent progresses in this field.


RESULTS
Creating an armed therapeutic viral platform, where the lytic property of viral infection coupled to virus-mediated interleukin delivery, may enhance the potential of virus-based therapeutics.


CONCLUSIONS
Oncolytic adenoviruses expressing interleukin may be a novel approach for tumour treatment. Combining advances in oncolytic adenoviruses with interleukin will open new avenues for treatment of human tumour.
Pei
Dong-Sheng
DS
Xuzhou Medical College, Laboratory of Biological Cancer Therapy, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, PR China. jnzheng@xzmc.edu.cn
Zheng
Jun-Nian
JN
D000256:Adenoviridae / Q000378:metabolism*; D000818:Animals; D006801:Humans; D007378:Interleukins / Q000096:biosynthesis*; D009369:Neoplasms / Q000628:therapy*; D050504:Oncolytic Viruses / Q000378:metabolism*
D007378:Interleukins